MedTrace Logo

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

NCT00241241 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-10-21

No results posted yet for this study

Summary

Interferon alfa is an effective treatment of polycythemia vera (PV), but about 20% of patients discontinue their treatment because of side effects and treatment schedule (three times per week administration). The pegylated form of interferon alfa-2a has shown a better tolerance in hepatitis patients and is administered only once a week. The purpose of this study is to determine efficacy and safety of pegylated interferon alfa-2a in the treatment of PV patients.

Conditions

Interventions

DRUG

pegylated interferon-alfa 2a

Sponsors & Collaborators

  • PV-Nord

    lead OTHER

Principal Investigators

  • Jean-Jacques Kiladjian, MD · PV-Nord

  • Pierre Fenaux, MD, PhD · PV-Nord

  • Christine Chomienne, MD, PhD · PV-Nord

  • Sylvia Bellucci, MD · PV-Nord

  • Bruno Cassinat, MD · PV-Nord

  • Marie-Jose Grange, MD · PV-Nord

  • Nathalie Cambier, MD · PV-Nord

  • Jean-Francois Bernard, MD · PV-Nord

  • Philippe Rousselot, MD · PV-Nord

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-10-31
Completion
2008-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241241 on ClinicalTrials.gov